Lawsuit: Investors Blind to Ocular Therapeutix’s Quality Issues

New to ClassAction.org? Read our Newswire Disclaimer

Ocular Therapeutix, Inc. and four executives are facing a stockholder’s claims that they misled investors about the quality and future success of Dextenza – a drug currently undergoing clinical trials for the treatment of certain eye conditions. According to the suit, Ocular’s manufacturing processes were under FDA investigation, but the company’s executives were optimistic about their ability to comply with regulations. The complaint alleges, however, that an article was released about the company on July 6, 2017 that claimed its “whole approach to manufacturing and patient safety is highly questionable.” The article supposedly referenced several of Ocular’s FDA notices and revealed to the public that more than half of its manufactured lots contained “bad product.” Following this article and another that accused the company of similar quality issues, Ocular stock fell over 30%, the plaintiff claims. He argues that the company and its executives deceived investors and caused them to suffer financial loss when the truth was revealed about its inability to deliver on its promises.